These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950 [Abstract] [Full Text] [Related]
6. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, Watari J, Miwa H. Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436 [Abstract] [Full Text] [Related]
10. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study. Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S. Adv Ther; 2016 Sep; 33(9):1519-35. PubMed ID: 27432383 [Abstract] [Full Text] [Related]
11. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Mochizuki S, Matsuo K, Isomura Y, Seto M, Suzuki N, Suzuki H, Yamamoto S, Sugimoto T, Omae T, Okamoto M, Watabe H, Togo G, Takano N, Fukui K, Ito Y, Koike K. J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444 [Abstract] [Full Text] [Related]
13. Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M. World J Gastroenterol; 2017 Jan 28; 23(4):668-675. PubMed ID: 28216974 [Abstract] [Full Text] [Related]
14. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China. Gao W, Teng G, Wang C, Xu Y, Li Y, Cheng H. Helicobacter; 2022 Oct 28; 27(5):e12918. PubMed ID: 35877765 [Abstract] [Full Text] [Related]
15. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Gut; 2016 Sep 28; 65(9):1439-46. PubMed ID: 26935876 [Abstract] [Full Text] [Related]
18. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori. Bunchorntavakul C, Buranathawornsom A. J Gastroenterol Hepatol; 2021 Dec 28; 36(12):3308-3313. PubMed ID: 34622504 [Abstract] [Full Text] [Related]
19. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T, Ishii M, Kamada T, Haruma K, Graham DY. Dig Dis Sci; 2016 Nov 28; 61(11):3215-3220. PubMed ID: 27659671 [Abstract] [Full Text] [Related]
20. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. Yang C, Li S, Huang T, Lin H, Jiang Z, He Y, Yuan J, An H. J Clin Pharm Ther; 2022 Jul 28; 47(7):897-904. PubMed ID: 35247003 [Abstract] [Full Text] [Related] Page: [Next] [New Search]